查看“艾瑞颐”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>[[艾瑞颐]]</strong>（通用名：<strong>[[氟唑帕利]]([[Fluzoparib]])</strong>）是由中国<strong>[[恒瑞医药]]</strong>自主研发的一种强效、口服小分子<strong>[[多聚ADP核糖聚合酶]]([[PARP]])</strong>抑制剂。该药物通过靶向抑制[[PARP1]]和[[PARP2]]酶活性，并产生显著的<strong>[[PARP捕获]]</strong>效应，利用<strong>[[合成致死]]</strong>原理精准杀伤伴有<strong>[[BRCA1]]/[[2]]</strong>突变或<strong>[[同源重组修复缺陷]]([[HRD]])</strong>的肿瘤细胞。在2026年的临床实践中，[[艾瑞颐]]已成为中国晚期<strong>[[上皮性卵巢癌]]</strong>、<strong>[[输卵管癌]]</strong>及<strong>[[原发性腹膜癌]]</strong>一线维持治疗的基石药物，并在<strong>[[小细胞肺癌]]</strong>及<strong>[[乳腺癌]]</strong>领域展现出强劲的临床潜力。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">艾瑞颐</div>
            <div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">氟唑帕利 (Fluzoparib)·点击展开</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 25px; text-align: center; background-color: #f8fafc;">
                <div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);">
                     <div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Fluzoparib Molecular View</div>
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">研发代码：[[SHR3162]]</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">核心靶点</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[PARP1]]•[[PARP2]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P09874</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发公司</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">恒瑞医药([[Hengrui]])</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">445.41Da</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">剂型</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">口服胶囊</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">中国医保</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;"><strong>[[NRDL]]常规准入</strong></td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026地位</th>
                    <td style="padding: 12px; color: #1e40af;">国产PARPi领军药物</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：多靶点阻断与DNA捕获</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        [[艾瑞颐]]的作用核心在于破坏肿瘤细胞的[[DNA]]损伤修复平衡，其药理特征在2026年的分子生物学研究中被深度解析：
    </p>
    [Image showing Fluzoparib trapping PARP complex on DNA strand]
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>竞争性抑制 NAD+ 结合：</strong>
            [[氟唑帕利]]通过与[[NAD+]]竞争[[PARP]]酶的活性位点，阻断受损[[DNA]]的聚腺苷二磷酸核糖基化过程，使单链断裂无法修复。</li>
        <li style="margin-bottom: 12px;"><strong>高效 PARP 捕获效应：</strong>
            2026年研究指出，[[艾瑞颐]]能将[[PARP]]酶牢固锁定在[[DNA]]损伤部位形成稳定的复合物。这种物理性屏障在细胞进入[[S期]]复制时会导致复制叉坍塌，将单链断裂转化为致死性的<strong>[[双链断裂]]([[DSBs]])</strong>。</li>
        <li style="margin-bottom: 12px;"><strong>合成致死选择性：</strong>
            具有<strong>[[BRCA]]</strong>突变或<strong>[[HRD]]</strong>阳性的肿瘤细胞缺乏高保真的同源重组修复能力。在这种背景下，[[艾瑞颐]]诱导的损伤无法被修复，从而精准引导癌细胞进入程序性死亡，而正常细胞则不受影响。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026临床产出与适应症版图</h2>

    <div style="overflow-x: auto; margin: 30px auto; max-width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">适应症领域</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">2026核心临床证据(研究名称)</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">临床价值/地位</th>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">铂敏感复发卵巢癌</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">FZOL-301研究：无论[[gBRCA]]状态，显著延长[[PFS]]。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>标准一线维持</strong>。国产同类首选。</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">gBRCA突变乳腺癌</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">对比解救化疗展现了显著的[[ORR]]及生活质量优势。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>精准挽救疗法</strong>。打破传统化疗局限。</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">小细胞肺癌([[SCLC]])</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">2026年III期数据：联合<strong>[[阿替利珠单抗]]</strong>增效。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>联合免疫新高度</strong>。跨癌种临床探索。</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗策略：全病程精准管理</h2>
    <p style="margin: 15px 0; text-align: justify;">
        针对[[艾瑞颐]]的应用，2026年指南强调了“疗效增强与毒性控制”的双重优化：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>HRD 状态引导：</strong>2026版专家共识强制推荐卵巢癌患者进行<strong>[[HRD]]</strong>基因组疤痕检测。阳性患者使用[[艾瑞颐]]维持治疗，五年生存率提升幅度具有显著统计学意义。</li>
        <li style="margin-bottom: 12px;"><strong>血液学安全性监控：</strong>针对常见的<strong>[[贫血]]</strong>及<strong>[[中性粒细胞减少]]</strong>，2026规范要求在用药首月每周监测血常规，并在出现2级以上毒性时实施“减量-恢复”梯度方案。</li>
        <li style="margin-bottom: 12px;"><strong>血管协同方案：</strong>在复发性肿瘤中，[[氟唑帕利]]联合<strong>[[阿帕替尼]]</strong>的“双艾”方案被广泛采用。利用抗血管生成药物改善肿瘤缺氧环境，从而克服[[PARPi]]的潜在耐药。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2>
    <div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;">
        <ul style="margin: 0; padding-left: 20px; color: #334155;">
            <li style="margin-bottom: 8px;"><strong>[[合成致死]]([[SyntheticLethality]])：</strong>[[艾瑞颐]]治疗的核心逻辑，针对DNA修复通路“双重缺失”的精准打击。</li>
            <li style="margin-bottom: 8px;"><strong>[[HRD]]([[同源重组修复缺陷]])：</strong>评价[[艾瑞颐]]临床获益人群广度的核心分子指标。</li>
            <li style="margin-bottom: 8px;"><strong>[[BRCA1]]/[[BRCA2]]：</strong>最经典、证据最充分的[[PARPi]]药效预测基因。</li>
            <li style="margin-bottom: 8px;"><strong>[[奥拉帕利]]：</strong>全球首款[[PARP]]抑制剂，[[艾瑞颐]]在多项研究中与其进行对比或补充。</li>
        </ul>
    </div>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Li W,et al.(2021/2025Revision).</strong> <em>Fluzoparib monotherapy in patients with germline BRCA1/2-mutated recurrence ovarian cancer:A multi-center, single-arm, phase II study.</em> <strong>[[The Lancet Oncology]]</strong>.<br>
            <span style="color: #475569;">[权威点评]：该项具有里程碑意义的研究确立了国产[[PARP]]抑制剂在耐药性卵巢癌中的单药救命地位。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>[[CSCO]]妇科肿瘤诊疗指南(2026版).</strong> <em>氟唑帕利在卵巢癌全人群维持治疗中的应用路径与安全性共识.</em><br>
            <span style="color: #475569;">[权威点评]：指南明确肯定了[[艾瑞颐]]在亚洲人群中优化的药代动力学及更好的耐受特征。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            艾瑞颐 (Fluzoparib) · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td>
                <td style="padding: 10px 15px; color: #334155;">[[PARP1]]•[[PARP2]]•[[BRCA1]]•[[BRCA2]]•[[RAD51]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">联合方案</td>
                <td style="padding: 10px 15px; color: #334155;">[[艾瑞颐]]+[[阿帕替尼]]•[[艾瑞颐]]+[[卡瑞利珠单抗]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">典型毒性</td>
                <td style="padding: 10px 15px; color: #334155;">[[贫血]]•[[血小板减少]]•[[恶心]]•[[疲劳]]</td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">诊断指标</td>
                <td style="padding: 10px 15px; color: #334155;">[[CA125]]•[[HRD评分]]•[[gBRCA检测]]</td>
            </tr>
        </table>
    </div>

</div>